Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Part A of the study is an open-label design with dosing of SAGE-217 for 14 days.
Part B of the study is a randomized, double-blind, parallel-group, placebo-controlled design. Eligible participants were randomized to SAGE-217 or placebo for 14 days.
This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant has a diagnosis of Major Depressive Disorder that has been present for at least a 4-week period as diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)
You may not be if
Participant has a history of suicide attempt
Participant has a history of treatment-resistant depression, defined as persistent depressive symptoms despite treatment with adequate doses of antidepressants from two different classes for an adequate amount of time
Participant has active psychosis
Participant has a medical history of seizures
Participant has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder